Hepatocellular carcinoma(HCC),which is essentially primary liver cancer,is closely related to CD8^(+)T cell immune infiltration and immune suppression.We constructed a CD8^(+)T cells related risk score model to predic...Hepatocellular carcinoma(HCC),which is essentially primary liver cancer,is closely related to CD8^(+)T cell immune infiltration and immune suppression.We constructed a CD8^(+)T cells related risk score model to predict the prognosis of HCC patients and provided therapeutic guidance based on the risk score.Using integrated bulk RNA sequencing(RNA-seq)and single-cell RNA sequencing(scRNA-seq)datasets,we identified stable CD8^(+)T cell signatures.Based on these signatures,a 3-gene risk score model,comprised of KLRB1,RGS 2,and TNFRSF1B was constructed.The risk score model was well validated through an independent external validation cohort.We divided patients into high-risk and low-risk groups according to the risk score and compared the differences in immune microenvironment between these two groups.Compared with low-risk patients,high-risk patients have higher M2-type macrophage content(P<0.0001)and lower CD8^(+)T cells infiltration(P<0.0001).High-risk patients predict worse response to immunotherapy treatment than low-risk patients(P<0.01).Drug sensitivity analysis shows that PI3K-β inhibitor AZD6482 and TGFβRII inhibitor SB505124 may be suitable therapies for high-risk patients,while the IGF-1R inhibitor BMS-754807 or the novel pyrimidine-based anti-tumor metabolic drug Gemcitabine could be potential therapeutic choices for low-risk patients.Moreover,expression of these 3-gene model was verified by immunohistochemistry.In summary,the establishment and validation of a CD8^(+)T cell-derived risk model can more accurately predict the prognosis of HCC patients and guide the construction of personalized treatment plans.展开更多
目的检测免疫性血小板减少症(ITP)患者外周血中CD8^+CD28^-调节性T细胞(Treg)、血小板特异性自身抗体、细胞因子的表达水平,分析其在ITP发病机制以及临床治疗中的意义。方法 73例ITP患者分为激素治疗组( n =42)、重组人粒血小板生成素(r...目的检测免疫性血小板减少症(ITP)患者外周血中CD8^+CD28^-调节性T细胞(Treg)、血小板特异性自身抗体、细胞因子的表达水平,分析其在ITP发病机制以及临床治疗中的意义。方法 73例ITP患者分为激素治疗组( n =42)、重组人粒血小板生成素(rhTPO)治疗组( n =31),并根据治疗效果分为有效组和无效组。流式细胞术检测患者治疗前后外周血CD8^+CD28^- Treg的表达,流式微球技术检测患者外周血血小板特异性自身抗体的表达。ELISA法检测患者治疗前后转化生长因子(TGF)-β1、白介素(IL)-10和干扰素(IFN)-γ表达水平。以30例健康体检者作为正常对照组。结果① 73例ITP患者治疗前CD8^+CD28^-Treg及细胞因子IL-10、TGF-β1的表达低于正常对照组,IFN-γ表达高于正常对照组( P <0.05),激素及rhTPO治疗后有效组CD8^+CD28^- Treg、IL-10、TGF-β1的表达均比治疗前显著上升,IFN-γ的表达较治疗前显著降低( P <0.05)。无效组CD8^+CD28^- Treg、IFN-γ、IL-10、TGF-β1的表达和治疗前相比均未有明显变化。②根据受试者工作特征曲线(ROC),激素组治疗前CD8^+CD28^-Treg的临界值为14.35,此时预测激素疗效的敏感性和特异性分别为66.7%和73.3%。27例有效者中小于14.35的有18例(66.7%),15例无效者中大于14.35的有11例(73.3%)。rhTPO组治疗前CD8^+CD28^-Treg的临界值为15.45,此时预测rhTPO疗效的敏感性和特异性分别为63.6%和88.9%。22例有效者中大于15.45的有14例(63.6%),9例无效者中小于15.45的有8例(88.9%)。③激素组抗血小板膜糖蛋白Ib(GPIb)抗体阳性患者18例,治疗后有效率44.4%,抗GPIb抗体阴性24例,有效率79.1%,两者比较差异有统计学意义( P <0.05)。结论 CD8^+CD28^- Treg及相关细胞因子的表达异常参与了ITP的发病,激素和rhTPO可能通过改变这种异常发挥作用。治疗前检测CD8^+CD28^-Treg有助于预测激素及rhTPO的疗效。抗GPIb抗体阳性可能是激素治疗不敏感的影响因素之一。展开更多
基金国家自然科学基金项目(No.81902513)山西省应用基础研究计划项目(No.202303021211114 and 202103021224228)山西省高等教育百亿工程“科技引导”专项(No.BYJL047)资助。
文摘Hepatocellular carcinoma(HCC),which is essentially primary liver cancer,is closely related to CD8^(+)T cell immune infiltration and immune suppression.We constructed a CD8^(+)T cells related risk score model to predict the prognosis of HCC patients and provided therapeutic guidance based on the risk score.Using integrated bulk RNA sequencing(RNA-seq)and single-cell RNA sequencing(scRNA-seq)datasets,we identified stable CD8^(+)T cell signatures.Based on these signatures,a 3-gene risk score model,comprised of KLRB1,RGS 2,and TNFRSF1B was constructed.The risk score model was well validated through an independent external validation cohort.We divided patients into high-risk and low-risk groups according to the risk score and compared the differences in immune microenvironment between these two groups.Compared with low-risk patients,high-risk patients have higher M2-type macrophage content(P<0.0001)and lower CD8^(+)T cells infiltration(P<0.0001).High-risk patients predict worse response to immunotherapy treatment than low-risk patients(P<0.01).Drug sensitivity analysis shows that PI3K-β inhibitor AZD6482 and TGFβRII inhibitor SB505124 may be suitable therapies for high-risk patients,while the IGF-1R inhibitor BMS-754807 or the novel pyrimidine-based anti-tumor metabolic drug Gemcitabine could be potential therapeutic choices for low-risk patients.Moreover,expression of these 3-gene model was verified by immunohistochemistry.In summary,the establishment and validation of a CD8^(+)T cell-derived risk model can more accurately predict the prognosis of HCC patients and guide the construction of personalized treatment plans.
文摘目的检测免疫性血小板减少症(ITP)患者外周血中CD8^+CD28^-调节性T细胞(Treg)、血小板特异性自身抗体、细胞因子的表达水平,分析其在ITP发病机制以及临床治疗中的意义。方法 73例ITP患者分为激素治疗组( n =42)、重组人粒血小板生成素(rhTPO)治疗组( n =31),并根据治疗效果分为有效组和无效组。流式细胞术检测患者治疗前后外周血CD8^+CD28^- Treg的表达,流式微球技术检测患者外周血血小板特异性自身抗体的表达。ELISA法检测患者治疗前后转化生长因子(TGF)-β1、白介素(IL)-10和干扰素(IFN)-γ表达水平。以30例健康体检者作为正常对照组。结果① 73例ITP患者治疗前CD8^+CD28^-Treg及细胞因子IL-10、TGF-β1的表达低于正常对照组,IFN-γ表达高于正常对照组( P <0.05),激素及rhTPO治疗后有效组CD8^+CD28^- Treg、IL-10、TGF-β1的表达均比治疗前显著上升,IFN-γ的表达较治疗前显著降低( P <0.05)。无效组CD8^+CD28^- Treg、IFN-γ、IL-10、TGF-β1的表达和治疗前相比均未有明显变化。②根据受试者工作特征曲线(ROC),激素组治疗前CD8^+CD28^-Treg的临界值为14.35,此时预测激素疗效的敏感性和特异性分别为66.7%和73.3%。27例有效者中小于14.35的有18例(66.7%),15例无效者中大于14.35的有11例(73.3%)。rhTPO组治疗前CD8^+CD28^-Treg的临界值为15.45,此时预测rhTPO疗效的敏感性和特异性分别为63.6%和88.9%。22例有效者中大于15.45的有14例(63.6%),9例无效者中小于15.45的有8例(88.9%)。③激素组抗血小板膜糖蛋白Ib(GPIb)抗体阳性患者18例,治疗后有效率44.4%,抗GPIb抗体阴性24例,有效率79.1%,两者比较差异有统计学意义( P <0.05)。结论 CD8^+CD28^- Treg及相关细胞因子的表达异常参与了ITP的发病,激素和rhTPO可能通过改变这种异常发挥作用。治疗前检测CD8^+CD28^-Treg有助于预测激素及rhTPO的疗效。抗GPIb抗体阳性可能是激素治疗不敏感的影响因素之一。
